-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Private Companies Are Shanghai Labway Clinical Laboratory Co., Ltd.'s (SZSE:301060) Biggest Owners and Were Hit After Market Cap Dropped CN¥1.3b
Private Companies Are Shanghai Labway Clinical Laboratory Co., Ltd.'s (SZSE:301060) Biggest Owners and Were Hit After Market Cap Dropped CN¥1.3b
A look at the shareholders of Shanghai Labway Clinical Laboratory Co., Ltd. (SZSE:301060) can tell us which group is most powerful. The group holding the most number of shares in the company, around 54% to be precise, is private companies. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
And following last week's 10% decline in share price, private companies suffered the most losses.
Let's delve deeper into each type of owner of Shanghai Labway Clinical Laboratory, beginning with the chart below.
View our latest analysis for Shanghai Labway Clinical Laboratory
SZSE:301060 Ownership Breakdown September 11th 2022What Does The Institutional Ownership Tell Us About Shanghai Labway Clinical Laboratory?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
Institutions have a very small stake in Shanghai Labway Clinical Laboratory. That indicates that the company is on the radar of some funds, but it isn't particularly popular with professional investors at the moment. If the business gets stronger from here, we could see a situation where more institutions are keen to buy. When multiple institutional investors want to buy shares, we often see a rising share price. The past revenue trajectory (shown below) can be an indication of future growth, but there are no guarantees.
SZSE:301060 Earnings and Revenue Growth September 11th 2022Hedge funds don't have many shares in Shanghai Labway Clinical Laboratory. The company's largest shareholder is Shanghai Lanwei Investment Co., Ltd., with ownership of 37%. Weixiong Zeng is the second largest shareholder owning 13% of common stock, and Heilan Group Co., Ltd. holds about 11% of the company stock. Weixiong Zeng, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer.
To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
Insider Ownership Of Shanghai Labway Clinical Laboratory
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our information suggests that insiders maintain a significant holding in Shanghai Labway Clinical Laboratory Co., Ltd.. Insiders own CN¥1.8b worth of shares in the CN¥11b company. That's quite meaningful. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.
General Public Ownership
The general public, who are usually individual investors, hold a 25% stake in Shanghai Labway Clinical Laboratory. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Company Ownership
It seems that Private Companies own 54%, of the Shanghai Labway Clinical Laboratory stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Shanghai Labway Clinical Laboratory better, we need to consider many other factors. Case in point: We've spotted 2 warning signs for Shanghai Labway Clinical Laboratory you should be aware of, and 1 of them shouldn't be ignored.
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
看看上海朗威臨牀實驗室股份有限公司(深交所股票代碼:301060)的股東,就知道哪個集團最有權勢。持有該公司股份最多的集團,準確地説約為54%,是私營公司。也就是説,如果股價上漲,該集團將受益最大(如果股價下跌,該集團將損失最大)。
繼上週股價下跌10%之後,私營企業遭受的損失最大。
讓我們從下面的圖表開始,更深入地瞭解上海朗威臨牀實驗室的每種類型的所有者。
查看我們對上海朗威臨牀實驗室的最新分析
深交所:301060所有權明細2022年9月11日機構所有制對上海朗威臨牀實驗室有何啟示?
許多機構以一個接近當地市場的指數來衡量它們的表現。因此,他們通常更關注那些被納入主要指數的公司。
醫療機構在上海朗威臨牀實驗室的持股比例非常低。這表明該公司受到了一些基金的關注,但目前並不是特別受專業投資者的歡迎。如果業務從現在開始變得更強勁,我們可能會看到更多機構熱衷於購買的情況。當多家機構投資者想要購買股票時,我們經常會看到股價上漲。過去的收入軌跡(如下所示)可以預示未來的增長,但這並不能保證。
深交所:2022年9月11日收益和收入增長301060對衝基金在上海朗威臨牀實驗室的股份並不多。該公司第一大股東為上海藍威投資有限公司,持股37%。曾偉雄為第二大股東,持有13%的普通股,海瀾集團股份有限公司持有公司約11%的股份。作為第二大股東的曾偉雄也恰好持有首席執行官的頭銜。
為了讓我們的研究更有趣,我們發現,前兩名股東擁有公司的多數股權,這意味着他們足夠強大,可以影響公司的決策。
研究機構持股是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒,也可以達到同樣的效果。據我們所知,沒有分析師對該公司的報道,所以它很可能在雷達下飛行。
上海朗威臨牀實驗室的內部人所有權
不同國家對內部人的定義可能略有不同,但董事會成員總是算數的。公司管理層對董事會負責,董事會應代表股東的利益。值得注意的是,有時最高層管理人員本身也是董事會成員。
我通常認為內部人持股是一件好事。然而,在某些情況下,這會讓其他股東更難讓董事會對決策負責。
我們的信息顯示,內部人士持有上海朗威臨牀實驗室有限公司的大量股份。內部人士在這家價值110億元的公司中持有價值18億元的股份。這是很有意義的。大多數人會高興地看到董事會與他們一起投資。你可能希望訪問這張顯示內部人士最近交易的免費圖表。
一般公有制
公眾通常是個人投資者,他們持有上海朗威臨牀實驗室25%的股份。儘管這種規模的所有權可能不足以影響有利於他們的政策決定,但他們仍然可以對公司政策產生集體影響。
私營公司所有權
看起來,民營企業持有上海朗威臨牀實驗室54%的股份。私營公司可能是關聯方。有時,內部人士通過持有一傢俬人公司來對上市公司感興趣,而不是以個人身份。雖然很難得出任何大致的中風結論,但值得注意的是,這是一個值得進一步研究的領域。
接下來的步驟:
擁有一家公司股票的不同集團總是值得考慮的。但為了更好地瞭解上海朗威臨牀實驗室,我們還需要考慮許多其他因素。一個恰當的例子:我們發現了上海朗威臨牀實驗室的2個警示標誌你應該意識到,其中有一個是不應該被忽視的。
如果你更願意看看另一家公司--一家財務狀況可能更好的公司--那麼不要錯過這一點免費令人感興趣的公司名單,有強勁的財務數據支持。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧